SI-BONE CFO Maheshwari reports Rule 10b5-1 stock sales

Rhea-AI Filing Summary

SI-BONE, Inc. (SIBN) filed a Form 4 reporting stock sales by its Chief Financial Officer, Anshul Maheshwari. The CFO sold 1,200 shares of common stock on 11/21/2025 at a weighted-average price of about $20.0133 per share and an additional 100 shares on 11/25/2025 at $20.00 per share. These sales were made under a pre-arranged Rule 10b5-1 trading plan dated December 13, 2024, which is designed to allow insiders to sell stock according to a set schedule.

Following these transactions, Maheshwari beneficially owns 203,773 shares of SI-BONE common stock. This total includes 143,116 shares issuable upon settlement of restricted stock units, each representing a right to receive one share of common stock.

Insider Trade Summary

Net Seller: 1,300 shares ($26,016)

Net Sell 2 txns

Insider Maheshwari Anshul

Role Chief Financial Officer

Sold 1,300 shs ($26K)

Type	Security	Shares	Price	Value
Sale	Common Stock	100	$20.00	$2K
Sale	Common Stock	1,200	$20.0133	$24K

Holdings After Transaction: Common Stock — 203,773 shares (Direct)

Footnotes (1)

1. The sale reported on this Form 4 was effected pursuant to a 10b5-1 trading plan dated December 13th, 2024. The price reported in column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $20.00 to $20.02, inclusive. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes. Includes 143,116 shares issuable on settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one shares of the Issuer's common stock.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Maheshwari Anshul

(Last) (First) (Middle)

C/O SI-BONE, INC

471 EL CAMINO REAL, SUITE 101

(Street)

SANTA CLARA CA 95050

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
SI-BONE, Inc. [ SIBN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/21/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/21/2025		S(1)		1,200	D	$20.0133(2)	203,873	D
Common Stock	11/25/2025		S(1)		100	D	$20	203,773(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale reported on this Form 4 was effected pursuant to a 10b5-1 trading plan dated December 13th, 2024.

2. The price reported in column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $20.00 to $20.02, inclusive. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes.

3. Includes 143,116 shares issuable on settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one shares of the Issuer's common stock.

Remarks:

	/s/ Michael Pisetsky, Attorney-in-Fact for Anshul Maheshwari	11/25/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did SI-BONE (SIBN) disclose in this Form 4?

The filing reports that SI-BONEs Chief Financial Officer, Anshul Maheshwari, sold 1,200 shares of common stock on 11/21/2025 and 100 shares on 11/25/2025.

At what prices did the SI-BONE (SIBN) CFO sell shares?

On 11/21/2025, 1,200 shares were sold at a weighted-average price of $20.0133 per share, and on 11/25/2025, 100 shares were sold at $20.00 per share.

Was the SI-BONE (SIBN) insider sale under a Rule 10b5-1 plan?

Yes. The filing states the sale was effected pursuant to a Rule 10b5-1 trading plan dated December 13, 2024.

How many SI-BONE (SIBN) shares does the CFO own after these transactions?

After the reported sales, Chief Financial Officer Anshul Maheshwari beneficially owns 203,773 shares of SI-BONE common stock.

How many SI-BONE (SIBN) restricted stock units does the CFO hold?

The filing notes that the beneficial ownership figure includes 143,116 shares issuable upon settlement of restricted stock units, each convertible into one share of common stock.

Who signed the SI-BONE (SIBN) Form 4?

The Form 4 is signed by /s/ Michael Pisetsky as Attorney-in-Fact for Anshul Maheshwari, dated 11/25/2025.